<?xml version="1.0" encoding="utf-8"?>
	<collection>
		
	
		<source>SourceData</source>
		
	
		<date>2019-04-19</date>
		
	
		<key>sourcedata.key</key>
		
	
		<document>
			
		
			<id>5286375 Figure_1-A-B</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 1-A-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-A-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>Flow cytometry analysis of PD-L1 expression in (A) KPC and (B) Pan02 cells following treatment with gemcitabine and RT. Gemcitabine was diluted in DMSO (vehicle) and DMSO was used for the 'untreated' control group (mean ± SD, n=3, One-way ANOVA, Bonferroni test).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_1-C-D</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 1-C-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-C-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>Western blot analysis of indicated proteins in both KPC (C) and Pan02 (D) cells following radiation and chemotherapy ± AG490, a JAK/Stat kinase inhibitor. Actin represents loading control.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:Actin</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="156"/>
					
				
					<text>Actin</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_1-E-F</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 1-E-F</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-E-F</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>Flow cytometry analysis of PD-L1 after gemcitabine and RT (as described above) in KPC (E) and Pan02 (F) following Stat1 downregulation by siRNA (mean ± SD, n=3, Student's t-test). MFI, mean fluorescence index;</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_2-A</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 2-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Tumor growth delay was measured in the different groups, as indicated (n=6 mice per group). Anti-PD-L1 was given at days 0 3, 6 and 9 (black arrows). The average time (days) for tumors to reach a volume of 400 mm3 from day 0 is shown (means ± SD, n=1, One-way ANOVA, Bonferroni test). No weight loss was observed in the in vivo experiment</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_3-A</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 3-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Tumor growth delay was measured by treating tumor with RT (12 Gy or 5x3 Gy daily; initiated at day 0) and anti-PD-L1 alone or combination of RT (n=6 mice per group). Anti-PD-L1 was given at days 0, 3, 6 and 9 (black arrows). The radiosensitizing effect of anti-PD-L1 after 12 Gy and 5x3 Gy was assessed as shown by the capped lines (means ± SD, n=1, One-way ANOVA, Bonferroni test). No weight loss was observed in the in vivo experiment.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_4-A</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 4-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) KPC tumor growth delay after treatment with either 12 Gy (day 0), anti-PD-L1 (days 0, 3, 6 and 9; black arrows), anti-CD8 alone (days 0 3, 6 and 9) or their combinations, as indicated.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:CD8</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="122"/>
					
				
					<text>CD8</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_4-B</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 4-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) KPC tumor growth delay after treatment with either 5x3 Gy (day 0-4), anti-PD-L1 alone (days 0, 3, 6 and 9; black arrows), anti-CD8 alone (days 0, 3, 6 and 9) or their combinations, as indicated.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:CD8</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="131"/>
					
				
					<text>CD8</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_4-C</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 4-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C) KPC tumor growth delay after either simultaneous (day 0, 3, 6 and 9; black arrows-upper row) or sequential (day 6, 9, 13 and 16; black arrows-lower row) addition of anti-PD-L1 to RT (day 0). The average time (days) for tumors to reach a volume of 400 mm3 from day 0 for Figure 4A-C is also shown (means ± SD, n=1, One-way ANOVA, Bonferroni test). No weight loss was observed in the in vivo experiments.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_5-A</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 5-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Mice were treated with either gemcitabine (day 0, 3), anti-PD-L1 (day 4, 7, 10 and 13; black arrows), 12 Gy (day 4) alone or in combinations, as indicated (n=8 mice per group). The average time (days) for tumors to reach a volume of 400 mm3 from day 0 is shown (means ± SD, n=1, One-way ANOVA, Bonferroni test) No weight loss was observed in the in vivo experiment.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_5-B</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 5-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>RT plus anti-PD-L1 (B) reverses T-cell exhaustion . Bar graphs show quantitation of T cell activation markers in tumor samples based on flow cytometry analysis, as indicated (n=5 per group; means ± SD, n=1, One-way ANOVA, Bonferroni test).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_5-C</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 5-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>RT plus anti-PD-L1 (C) increases CD8:Treg ratio. Bar graphs show ratio of CD8:Treg ratio in tumor samples based on flow cytometry analysis, as indicated (n=5 per group; means ± SD, n=1, One-way ANOVA, Bonferroni test).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_6-A</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 6-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Representative images of livers from the different treatment groups, as indicated. The corresponding liver weights are shown below (n=6 mice per group).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286375 Figure_6-B</id>
			
		
			<infon key="sourcedata_document">2495</infon>
			
		
			<infon key="doi">10.15252/emmm.201606674</infon>
			
		
			<infon key="pmc_id">5286375</infon>
			
		
			<infon key="figure">Figure 6-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Flow cytometry analysis of CD45+CD8+, CD11b+Gr1+ and CD4+CD25+FOXP3+ cell populations in the livers of the mice from the different treatment groups, as indicated (n=5 per group; (means ± SD, n=1, One-way ANOVA, Bonferroni test).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:CD45</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="4" offset="31"/>
					
				
					<text>CD45</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		

	</collection>
